terazosin has been researched along with Blood Pressure, High in 111 studies
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia
| Excerpt | Relevance | Reference |
|---|---|---|
| "Terazosin, a new selective long-acting alpha1-adrenergic blocking agent, has been shown to be an effective once-daily antihypertensive agent in four of five randomized double-blind placebo-controlled studies of patients with mild to moderate hypertension." | 10.15 | Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy. ( Glassman, HN; Horton, JK; Jordan, DC; Luther, RR; Sperzel, WD; Steinberg, FJ, 1986) |
| "The present study aims to assess and compare the effects of carvedilol and terazosin plus enalapril on lower urinary tract symptoms (LUTS), the urine flow, and blood pressure (BP) in patients with moderate hypertension (HTN) and benign prostatic hyperplasia (BPH)." | 9.41 | A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia. ( DalirAkbari, N; Farshi, A; Khalili, M; Mahmoudinezhad, M; Zomorrodi, A, 2021) |
| "This prospective randomized double-blinded clinical trial was designed to explore the effects of amlodipine and the combination of amlodipine with terazosin in improving postvoid residual (PVR) in patients with lower urinary tract symptoms (LUTS) and concomitant hypertension." | 9.14 | [Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention]. ( Fang, J; Li, YL; Liu, HP; Qin, XH; Xu, XP; Yang, C; Zhang, X, 2009) |
| "We determined the efficacy and safety of a relatively high dose of terazosin (5mg) in Korean patients with lower urinary tract symptoms (LUTS), with or without concomitant hypertension." | 9.12 | High-dose terazosin therapy (5mg) in Korean patients with lower urinary tract symptoms with or without concomitant hypertension: a prospective, open-label study. ( Ku, JH; Kwak, C; Lee, JK, 2007) |
| "To review and assess the cardiovascular safety of the alpha1-blocker terazosin when used to treat symptomatic benign prostatic hyperplasia (BPH) in patients taking concurrent antihypertensive medications." | 9.09 | Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. ( Lowe, FC; Olson, PJ; Padley, RJ, 1999) |
| "The effects of the alpha-1-adrenergic blocker terazosin on blood pressure and fasting and postprandial glucose and lipid metabolism were assessed in type 2 diabetic patients with hypertension." | 9.09 | Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in type 2 diabetic patients with hypertension. ( Ferrara, LA; Imperatore, G; Iovine, C; Pasanisi, F; Vaccaro, O, 1999) |
| "A double-blind, double-dummy, parallel-group trial that used a predominantly Hispanic patient population with mild-to-moderate hypertension was designed to compare the efficacy, safety, and acceptability of monotherapy with either transdermal clonidine applied once a week or terazosin tablets taken once a day." | 9.08 | Alpha 2-agonist versus alpha 1-antagonist in mild-to-moderate hypertension: comparison of transdermal clonidine and terazosin monotherapies. ( Alvarez, C; Harris, SI, 1997) |
| "To determine the effects of terazosin on blood pressure and on antihypertensive therapy when used in managing benign prostatic hyperplasia (BPH)." | 9.08 | Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men. ( Kirby, RS, 1998) |
| "The effects of six weeks of treatment with the selective peripheral alpha 1-adrenoceptor blocker terazosin, or the selective beta 1-adrenoceptor blocker atenolol on blood pressure, exercise performance and blood lipid profile were compared in a single-blind, randomized, crossover study of 17 patients with mild-to-moderate essential hypertension." | 9.07 | A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension. ( Cleland, J; Coles, SJ; Humphreys, J; Ligueros, M; Unwin, R; Wilkins, MR, 1992) |
| "This study reviews and assesses the safety of terazosin for the treatment of symptomatic benign prostatic hyperplasia (BPH)." | 9.07 | Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. ( Lowe, FC, 1994) |
| "Terazosin is safe and effective in treating concomitant hypertension and BPH." | 9.07 | Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial. ( Guthrie, R, 1994) |
| "Terazosin is a selective alpha 1-adrenoceptor antagonist; its actions on the serum lipoprotein profile were compared with those of the cardioselective beta-adrenoceptor antagonist atenolol in 40 patients with mild to moderate hypertension." | 9.07 | Comparison of antihypertensive and lipid actions of terazosin and atenolol in essential hypertension. ( Guy, S; Humphreys, JE; Silke, B, 1992) |
| "The safety, efficacy and the effect on the plasma total cholesterol of once-daily terazosin hydrochloride administered as monotherapy was evaluated in 69 patients with mild-moderate untreated essential hypertension in this open, hospital, multi-centre, 3 month study." | 9.07 | A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with untreated essential hypertension. ( Coles, S; Lytle, T; Waite, MA, 1991) |
| "The safety, efficacy and the effect on the plasma total cholesterol of once-daily terazosin hydrochloride administered either as monotherapy or in combination with other antihypertensive therapy were evaluated in patients with mild-moderate uncontrolled essential hypertension in this U." | 9.07 | A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with essential hypertension. ( Coles, SJ; Lytle, TB; Waite, MA, 1991) |
| "The long-term treatment of essential hypertension with terazosin, a new once-a-day alpha 1-adrenergic blocking agent, was evaluated in 364 hypertensive patients who received total daily doses of 1 to 40 mg for 3 weeks to 56 months." | 9.06 | Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension. ( Estep, CB; Glassman, HN; Horton, JK; Jordan, DC; Luther, RR; Schmitz, PJ, 1988) |
| "In a multicenter, double-blind, placebo-controlled study, the efficacy and safety of terazosin and prazosin were compared in patients with mild to moderate essential hypertension." | 9.06 | Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension. ( Deger, G, 1986) |
| "The safety and efficacy of once-daily terazosin hydrochloride administered concomitantly with once-daily atenolol for the treatment of essential hypertension were evaluated in this double-blind, multiclinic, placebo-controlled study." | 9.06 | Concomitant administration of terazosin and atenolol for the treatment of essential hypertension. ( Holtzman, JL; Kaihlanen, PM; Lewin, AJ; Oberlin, JA; Rider, JA; Spindler, JS, 1988) |
| "The effect of withdrawal of terazosin therapy in patients with mild to moderate hypertension was assessed in two double-blind, placebo-controlled studies." | 9.06 | Effect of withdrawal of terazosin therapy in patients with hypertension. ( Ruoff, G, 1986) |
| "The safety and efficacy of once-daily terazosin as monotherapy were evaluated in five randomized, double-blind, placebo-controlled studies in which 351 patients with mild to moderate hypertension participated." | 9.06 | Terazosin: an effective once-daily monotherapy for the treatment of hypertension. ( Dauer, AD, 1986) |
| "Terazosin was effective in lowering blood pressure when administered alone (in dosages of 1 to 80 mg/day) and when prescribed (in dosages of 1 to 20 mg/day) in combination with other antihypertensive agents." | 7.77 | The safety and efficacy of terazosin in the treatment of essential hypertension in blacks. ( Saunders, E, 1991) |
| "Terazosin is a post-synaptic alpha 1-adrenoceptor antagonist with a similar pharmacodynamic profile to prazosin." | 7.76 | Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. ( Monk, JP; Titmarsh, S, 1987) |
| "The effect of enalapril and terazosin on serum lipid profile was investigated in 36 patients with primary hypertension and hypercholesterolemia (total cholesterol 5." | 7.68 | [Effect of enalapril and terazosin on lipid metabolism in patients with essential arterial hypertension and accompanying hypercholesterolemia]. ( Hańczycowa, H; Jordanek, P; Jurga, M; Ponikowski, P; Rotter, A; Sebzda, T; Spring, A, 1993) |
| "The antihypertensive effects of the selective alpha 1-adrenoceptor antagonist, terazosin, in black patients with uncomplicated, mild to moderate essential hypertension were examined retrospectively in seven randomized, double-blind, placebo-controlled trials conducted in the United States." | 7.68 | Efficacy of terazosin in the treatment of essential hypertension in blacks. ( Achari, R; Glassman, HN; Klepper, MJ; Laddu, AR; Luther, RR; Maurath, CJ, 1990) |
| "The effects of selective alpha 1-adrenergic blockade with the agent terazosin on blood pressure and cardiovascular pressor responsiveness as related to major pressor factors were assessed in 17 patients with mild to moderate essential hypertension (mean age +/- s." | 7.67 | Cardiovascular effects of short-term selective alpha 1-adrenergic blockade with terazosin in patients with essential hypertension. ( Beretta-Piccoli, C; Ferrier, C; Weidmann, P, 1985) |
| "Thirteen patients with essential hypertension were treated with an alpha 1-adrenoceptor antagonist, terazosin (1 to 4 mg/day) for 12 months." | 7.67 | Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment. ( Mikawa, M; Sasayama, S; Takata, M; Tomoda, F; Yasumoto, K; Yoshida, K, 1989) |
| "Two hundred twenty-six patients with mild to moderate hypertension were treated with terazosin in an open, multicenter study to determine the drug's long-term efficacy and safety." | 7.67 | Long-term experience with terazosin for treatment of mild to moderate hypertension. ( Mersey, JH, 1986) |
| "Terazosin is a selective alpha1-adrenoceptor antagonist." | 6.69 | Effects of oral and intravenous terazosin and head-up tilt on blood pressure responses in patients with hypertension. ( Achari, R; Baroldi, P; Cavanaugh, J; Cohen, A; Hosmane, B; Linnen, P, 1998) |
| "alpha-Blockers and calcium antagonists are commonly used in the treatment of hypertension, but few data are available concerning first dose or steady state (SS) hemodynamic and pharmacokinetic effects of these drugs when they are used in combination therapy." | 6.68 | Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions. ( Johnston, W; Laddu, AR; Lenz, ML; Pool, JL; Taylor, AA; Varghese, A, 1995) |
| " Terazosin, an alpha 1-adrenergic blocking agent, was given initially at the dosage of 1 mg daily." | 6.68 | Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension. ( Angeli-Greaves, M; Armas Padilla, MC; Armas-Hernández, MJ; Carvajal, AR; Guerrero Pajuelo, J; Hernández Hernández, R, 1996) |
| " Another multicenter trial reported that doxazosin therapy was effective at low doses; 76% of those responders achieved controlled blood pressure at a mean dosage of 3." | 6.66 | Efficacy and safety of doxazosin in hypertension therapy. ( Hayduk, K, 1987) |
| "Doxazosin is an effective, well-tolerated, once-daily antihypertensive agent; it is comparable with terazosin but at a lower daily dosage." | 6.66 | Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin. ( Hayduk, K; Schneider, HT, 1987) |
| "Terazosin is a new long-acting, selective alpha 1-adrenergic antagonist." | 6.37 | Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension. ( Eisen, G; Frishman, WH; Lapsker, J, 1988) |
| "Terazosin, a new selective long-acting alpha1-adrenergic blocking agent, has been shown to be an effective once-daily antihypertensive agent in four of five randomized double-blind placebo-controlled studies of patients with mild to moderate hypertension." | 6.15 | Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy. ( Glassman, HN; Horton, JK; Jordan, DC; Luther, RR; Sperzel, WD; Steinberg, FJ, 1986) |
| "The present study aims to assess and compare the effects of carvedilol and terazosin plus enalapril on lower urinary tract symptoms (LUTS), the urine flow, and blood pressure (BP) in patients with moderate hypertension (HTN) and benign prostatic hyperplasia (BPH)." | 5.41 | A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia. ( DalirAkbari, N; Farshi, A; Khalili, M; Mahmoudinezhad, M; Zomorrodi, A, 2021) |
| "Selected adverse events were evaluated from the combined randomized placebo-controlled clinical trials (once-a-day or twice-a-day; monotherapy or combination therapy) of terazosin in hypertensive patients." | 5.28 | Effect of age and dose on the incidence of adverse events in the treatment of hypertension in patients receiving terazosin. ( Hosmane, BS; Jordan, DC; Laddu, A; Maurath, CJ, 1992) |
| "To investigate the therapeutic efficacy and safety of Amlodipine alone or in combination with terazosin for the presence of lower urinary tract symptoms (LUTS) and hypertension." | 5.14 | Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double-blind clinical trial. ( Chen, G; Liu, H; Liu, P; Liu, Z; Mao, G; Na, Y; Qin, X; Wang, B; Wang, X; Xu, X, 2009) |
| "This prospective randomized double-blinded clinical trial was designed to explore the effects of amlodipine and the combination of amlodipine with terazosin in improving postvoid residual (PVR) in patients with lower urinary tract symptoms (LUTS) and concomitant hypertension." | 5.14 | [Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention]. ( Fang, J; Li, YL; Liu, HP; Qin, XH; Xu, XP; Yang, C; Zhang, X, 2009) |
| "The result suggested that the angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers and long-acting calcium antagonists were effective in treating essential hypertension, while the low-dose doxazosin, terazosin and torasemide can be used for combination therapy but not for monotherapy." | 5.12 | [Efficacy of monotherapy with 15 antihypertensive agents in treating essential hypertension assessed by 24-hour ambulatory blood pressure monitoring]. ( Cheng, XR; Hua, CX; Hua, L; Huang, Y; Kang, J; Li, N; Li, YS; Liu, H; Ming, GH; Pang, HM; Wang, L; Wu, Y; Xu, L; Xu, ZM, 2007) |
| "We determined the efficacy and safety of a relatively high dose of terazosin (5mg) in Korean patients with lower urinary tract symptoms (LUTS), with or without concomitant hypertension." | 5.12 | High-dose terazosin therapy (5mg) in Korean patients with lower urinary tract symptoms with or without concomitant hypertension: a prospective, open-label study. ( Ku, JH; Kwak, C; Lee, JK, 2007) |
| "To clarify the influence of hypertension on lower urinary tract symptoms (LUTS) we examined the relationship between blood pressure, LUTS, and the effect of terazosin on LUTS in patients with benign prostatic hyperplasia (BPH)." | 5.10 | Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. ( Gakiya, M; Goya, M; Hatano, T; Ikehara, A; Kadekawa, K; Nakayama, T; Nashiro, F; Ogawa, Y; Sugaya, K, 2003) |
| "To investigate the relationship among serum nitric oxide, D-dimer, blood pressure, dangerous states and target organ damage in essential hypertension and to evaluate the effects of enalapril and terazosin." | 5.10 | [Serum nitric oxide and D-dimer before and after administering antihypertensive drugs in essential hypertension]. ( Luo, JK; Sun, M; Zhang, WR, 2003) |
| "In an open multicenter prospective study, the effects of short-term (4 weeks, n = 101) and long-term (6 months, n = 38) terazosin treatment on blood pressure, serum lipids and safety in the patients with mild to moderate essential hypertension were observed." | 5.09 | Effect of terazosin on blood pressure and serum lipids. ( Cheng, L; Gong, P; Lu, Z; Tang, J; Zeng, F; Zhang, J, 1999) |
| "The effects of the alpha-1-adrenergic blocker terazosin on blood pressure and fasting and postprandial glucose and lipid metabolism were assessed in type 2 diabetic patients with hypertension." | 5.09 | Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in type 2 diabetic patients with hypertension. ( Ferrara, LA; Imperatore, G; Iovine, C; Pasanisi, F; Vaccaro, O, 1999) |
| "To review and assess the cardiovascular safety of the alpha1-blocker terazosin when used to treat symptomatic benign prostatic hyperplasia (BPH) in patients taking concurrent antihypertensive medications." | 5.09 | Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. ( Lowe, FC; Olson, PJ; Padley, RJ, 1999) |
| "To determine the effects of terazosin on blood pressure and on antihypertensive therapy when used in managing benign prostatic hyperplasia (BPH)." | 5.08 | Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men. ( Kirby, RS, 1998) |
| "A double-blind, double-dummy, parallel-group trial that used a predominantly Hispanic patient population with mild-to-moderate hypertension was designed to compare the efficacy, safety, and acceptability of monotherapy with either transdermal clonidine applied once a week or terazosin tablets taken once a day." | 5.08 | Alpha 2-agonist versus alpha 1-antagonist in mild-to-moderate hypertension: comparison of transdermal clonidine and terazosin monotherapies. ( Alvarez, C; Harris, SI, 1997) |
| "This study reviews and assesses the safety of terazosin for the treatment of symptomatic benign prostatic hyperplasia (BPH)." | 5.07 | Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. ( Lowe, FC, 1994) |
| "Terazosin is safe and effective in treating concomitant hypertension and BPH." | 5.07 | Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial. ( Guthrie, R, 1994) |
| "The safety, efficacy and the effect on the plasma total cholesterol of once-daily terazosin hydrochloride administered as monotherapy was evaluated in 69 patients with mild-moderate untreated essential hypertension in this open, hospital, multi-centre, 3 month study." | 5.07 | A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with untreated essential hypertension. ( Coles, S; Lytle, T; Waite, MA, 1991) |
| "This open, multicenter phase III study was designed to assess the efficacy and long-term safety of terazosin (1 to 40 mg/day), alone or in combination with other antihypertensive drugs, in 364 patients with mild to moderate essential hypertension." | 5.07 | Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents. ( Cohen, JD, 1991) |
| "The effects of six weeks of treatment with the selective peripheral alpha 1-adrenoceptor blocker terazosin, or the selective beta 1-adrenoceptor blocker atenolol on blood pressure, exercise performance and blood lipid profile were compared in a single-blind, randomized, crossover study of 17 patients with mild-to-moderate essential hypertension." | 5.07 | A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension. ( Cleland, J; Coles, SJ; Humphreys, J; Ligueros, M; Unwin, R; Wilkins, MR, 1992) |
| "Terazosin is a selective alpha 1-adrenergic-blocking agent indicated for the treatment of hypertension." | 5.07 | Antihypertensive dose-response relationships: studies with the selective alpha 1-blocking agent terazosin. ( Cheung, DG; Laddu, AR; Luther, RR; Weber, MA, 1991) |
| "Terazosin is a selective alpha 1-adrenoceptor antagonist; its actions on the serum lipoprotein profile were compared with those of the cardioselective beta-adrenoceptor antagonist atenolol in 40 patients with mild to moderate hypertension." | 5.07 | Comparison of antihypertensive and lipid actions of terazosin and atenolol in essential hypertension. ( Guy, S; Humphreys, JE; Silke, B, 1992) |
| "The safety, efficacy and the effect on the plasma total cholesterol of once-daily terazosin hydrochloride administered either as monotherapy or in combination with other antihypertensive therapy were evaluated in patients with mild-moderate uncontrolled essential hypertension in this U." | 5.07 | A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with essential hypertension. ( Coles, SJ; Lytle, TB; Waite, MA, 1991) |
| "The safety and efficacy of once-daily terazosin hydrochloride administered concomitantly with once-daily atenolol for the treatment of essential hypertension were evaluated in this double-blind, multiclinic, placebo-controlled study." | 5.06 | Concomitant administration of terazosin and atenolol for the treatment of essential hypertension. ( Holtzman, JL; Kaihlanen, PM; Lewin, AJ; Oberlin, JA; Rider, JA; Spindler, JS, 1988) |
| "In a randomized, double-blind, placebo-controlled, multicenter trial, the efficacy and safety of terazosin in combination with other antihypertensive agents were assessed using patients with inadequately controlled essential hypertension (supine diastolic blood pressure 95 mm Hg or greater)." | 5.06 | Experience with terazosin administered in combination with other antihypertensive agents. ( Chrysant, SG, 1986) |
| "The safety and efficacy of once-daily terazosin as monotherapy were evaluated in five randomized, double-blind, placebo-controlled studies in which 351 patients with mild to moderate hypertension participated." | 5.06 | Terazosin: an effective once-daily monotherapy for the treatment of hypertension. ( Dauer, AD, 1986) |
| "The effect of withdrawal of terazosin therapy in patients with mild to moderate hypertension was assessed in two double-blind, placebo-controlled studies." | 5.06 | Effect of withdrawal of terazosin therapy in patients with hypertension. ( Ruoff, G, 1986) |
| "The efficacy and safety of terazosin were compared with those of other antihypertensive drugs in three parallel-group, randomized, double-blind studies in which 133 patients with mild to moderate hypertension participated." | 5.06 | Comparative trials of terazosin with other antihypertensive agents. ( Ruoff, G, 1986) |
| "In a multicenter, double-blind, placebo-controlled study, the efficacy and safety of terazosin and prazosin were compared in patients with mild to moderate essential hypertension." | 5.06 | Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension. ( Deger, G, 1986) |
| "A total of 713 patients with hypertension were evaluated in eight randomized, double-blind, placebo-controlled trials of terazosin administered in single daily doses ranging from 1 to 40 mg." | 5.06 | Efficacy of terazosin as an antihypertensive agent. ( Glassman, HN; Jordan, DC; Luther, RR; Sperzel, WD, 1986) |
| "The effect of the selective alpha 1-antagonist terazosin on serum lipoproteins and certain blood pressure-regulating factors was assessed in 15 patients with essential hypertension." | 5.06 | Alpha-1-adrenergic blockade and lipoprotein metabolism in essential hypertension. ( Beretta-Piccoli, C; Ferrier, C; Mordasini, R; Weidmann, P, 1986) |
| "The long-term treatment of essential hypertension with terazosin, a new once-a-day alpha 1-adrenergic blocking agent, was evaluated in 364 hypertensive patients who received total daily doses of 1 to 40 mg for 3 weeks to 56 months." | 5.06 | Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension. ( Estep, CB; Glassman, HN; Horton, JK; Jordan, DC; Luther, RR; Schmitz, PJ, 1988) |
| "To evaluate risk factors (hypertension, diabetes mellitus, and current tamsulosin, alfuzosin, terazosin, or doxazosin use) for intraoperative floppy iris syndrome (IFIS) in patients undergoing phacoemulsification cataract surgery." | 4.87 | Risk factors for intraoperative floppy iris syndrome: a meta-analysis. ( Chatziralli, IP; Sergentanis, TN, 2011) |
| "For various reasons, the alpha 1-receptor blocker prazosin has been used infrequently as initial therapy for hypertension." | 4.78 | Alpha-blocker therapy of hypertension. An unfulfilled promise. ( Kaplan, NM; Khoury, AF, 1991) |
| "Terazosin (Hytrin; Abbott Laboratories, North Chicago, IL) is a new, selective alpha 1-adrenoceptor blocking agent used on once-a-day basis for therapy of mild-to-moderate hypertension." | 4.78 | Terazosin: a new alpha adrenoceptor blocking drug. ( Achari, R; Laddu, A, 1992) |
| "Terazosin is a new, selective, alpha 1-adrenoceptor antagonist which is structurally similar to prazosin and of similar therapeutic efficacy in the treatment of mild-to-moderate essential hypertension." | 4.77 | Terazosin: a new antihypertensive agent with favorable effects on lipids. ( Luther, RR, 1989) |
| "Terazosin was effective in lowering blood pressure when administered alone (in dosages of 1 to 80 mg/day) and when prescribed (in dosages of 1 to 20 mg/day) in combination with other antihypertensive agents." | 3.77 | The safety and efficacy of terazosin in the treatment of essential hypertension in blacks. ( Saunders, E, 1991) |
| "Terazosin is a post-synaptic alpha 1-adrenoceptor antagonist with a similar pharmacodynamic profile to prazosin." | 3.76 | Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. ( Monk, JP; Titmarsh, S, 1987) |
| "A number of agents are now available to treat hypertension." | 3.76 | alpha 1-antagonists in the treatment of hypertension. ( Grimm, RH, 1989) |
| "Treatment of benign prostatic hyperplasia (BPH) with nonselective alpha1 antagonists such as terazosin, doxazosin, and prazosin results in blood pressure reduction due to vasodilation." | 3.71 | Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. ( Chao, J; Chrischilles, E; Gilden, D; Kreder, KJ; Rubenstein, L; Shah, H, 2001) |
| "The antihypertensive effects of the selective alpha 1-adrenoceptor antagonist, terazosin, in black patients with uncomplicated, mild to moderate essential hypertension were examined retrospectively in seven randomized, double-blind, placebo-controlled trials conducted in the United States." | 3.68 | Efficacy of terazosin in the treatment of essential hypertension in blacks. ( Achari, R; Glassman, HN; Klepper, MJ; Laddu, AR; Luther, RR; Maurath, CJ, 1990) |
| "The effect of enalapril and terazosin on serum lipid profile was investigated in 36 patients with primary hypertension and hypercholesterolemia (total cholesterol 5." | 3.68 | [Effect of enalapril and terazosin on lipid metabolism in patients with essential arterial hypertension and accompanying hypercholesterolemia]. ( Hańczycowa, H; Jordanek, P; Jurga, M; Ponikowski, P; Rotter, A; Sebzda, T; Spring, A, 1993) |
| "The effects of terazosin, a new, selective, alpha 1-adrenoceptor antagonist, on the serum lipid levels were examined in 103 black patients with uncomplicated, mild to moderate essential hypertension in six randomized, double-blind, placebo-controlled trials conducted in the United States." | 3.68 | Effects of terazosin on serum lipid levels in hypertensive blacks. ( Achari, R; Glassman, HN; Klepper, MJ; Laddu, AR; Luther, RR; Maurath, CJ, 1990) |
| "The effects of selective alpha 1-adrenergic blockade with the agent terazosin on blood pressure and cardiovascular pressor responsiveness as related to major pressor factors were assessed in 17 patients with mild to moderate essential hypertension (mean age +/- s." | 3.67 | Cardiovascular effects of short-term selective alpha 1-adrenergic blockade with terazosin in patients with essential hypertension. ( Beretta-Piccoli, C; Ferrier, C; Weidmann, P, 1985) |
| "The pharmacokinetics of terazosin have been assessed in human volunteers, hypertensive patients, a limited number of elderly volunteers, and a small number of patients with congestive heart failure." | 3.67 | Pharmacokinetics of terazosin. ( Sonders, RC, 1986) |
| "The effects of selective alpha 1-adrenergic blockade with terazosin on blood pressure and cardiovascular pressor responsiveness were assessed in 17 subjects with mild to moderate essential hypertension (mean age, 48 +/- 2 [SEM] years)." | 3.67 | Alpha 1-adrenergic blockade and cardiovascular pressor responses in essential hypertension. ( Beretta-Piccoli, C; Ferrier, C; Weidmann, P, 1986) |
| "Two hundred twenty-six patients with mild to moderate hypertension were treated with terazosin in an open, multicenter study to determine the drug's long-term efficacy and safety." | 3.67 | Long-term experience with terazosin for treatment of mild to moderate hypertension. ( Mersey, JH, 1986) |
| "Thirteen patients with essential hypertension were treated with an alpha 1-adrenoceptor antagonist, terazosin (1 to 4 mg/day) for 12 months." | 3.67 | Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment. ( Mikawa, M; Sasayama, S; Takata, M; Tomoda, F; Yasumoto, K; Yoshida, K, 1989) |
| "The safety of terazosin, an effective agent for the treatment of hypertension, was assessed by analyzing data from 1,006 hypertensive patients who were enrolled in short-term and/or long-term studies." | 3.67 | Overall safety of terazosin as an antihypertensive agent. ( Glassman, HN; Jordan, DC; Luther, RR; Sperzel, WD, 1986) |
| " No unknown adverse reactions were observed in either groups, and the drugs were shown to be highly safe." | 2.70 | [The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy]. ( Fujioka, T; Goto, Y; Isurugi, K; Katoh, T; Numasato, S; Obara, W; Omori, S; Suzuki, Y, 2001) |
| "nilvadipine or terazosin was administered for 2 weeks in a randomized crossover manner." | 2.69 | Comparative efficacies of a calcium antagonist and an alpha1 blocker in elderly hypertensive patients with stroke. ( Abe, I; Fujishima, M; Hasuo, Y; Nishino, Y; Onaka, U; Setoguchi, M, 1998) |
| "Terazosin is a selective alpha1-adrenoceptor antagonist." | 2.69 | Effects of oral and intravenous terazosin and head-up tilt on blood pressure responses in patients with hypertension. ( Achari, R; Baroldi, P; Cavanaugh, J; Cohen, A; Hosmane, B; Linnen, P, 1998) |
| "A double-blind, randomized, placebo-controlled, multicenter study was conducted to describe the dose-response curve for terazosin on blood pressure." | 2.69 | The relationship between terazosin dose and blood pressure response in hypertensive patients. ( Achari, R; Bonacci, E; Hosmane, B; O'Dea, R, 2000) |
| " Terazosin, an alpha 1-adrenergic blocking agent, was given initially at the dosage of 1 mg daily." | 2.68 | Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension. ( Angeli-Greaves, M; Armas Padilla, MC; Armas-Hernández, MJ; Carvajal, AR; Guerrero Pajuelo, J; Hernández Hernández, R, 1996) |
| "alpha-Blockers and calcium antagonists are commonly used in the treatment of hypertension, but few data are available concerning first dose or steady state (SS) hemodynamic and pharmacokinetic effects of these drugs when they are used in combination therapy." | 2.68 | Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions. ( Johnston, W; Laddu, AR; Lenz, ML; Pool, JL; Taylor, AA; Varghese, A, 1995) |
| "Terazosin was administered alone and in combination with other antihypertensive agents." | 2.66 | Clinical trials with terazosin. General methods. ( Glassman, HN; Luther, RR; Sperzel, WD, 1986) |
| " Another multicenter trial reported that doxazosin therapy was effective at low doses; 76% of those responders achieved controlled blood pressure at a mean dosage of 3." | 2.66 | Efficacy and safety of doxazosin in hypertension therapy. ( Hayduk, K, 1987) |
| "Doxazosin is an effective, well-tolerated, once-daily antihypertensive agent; it is comparable with terazosin but at a lower daily dosage." | 2.66 | Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin. ( Hayduk, K; Schneider, HT, 1987) |
| "The short-term antihypertensive efficacy and safety of terazosin when administered with a diuretic were assessed in three randomized, double-blind, placebo-controlled studies." | 2.66 | Cumulative experience with terazosin administered in combination with diuretics. ( Rudd, P, 1986) |
| " Adverse effects were mild." | 2.66 | Efficacy and safety of intravenous terazosin in hypertensive patients. A preliminary report. ( Cohen, A, 1986) |
| "Terazosin is a new, long-acting, selective, postsynaptic alpha 1-adrenergic receptor antagonist with a chemical structure similar to that of prazosin." | 2.38 | Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events. ( Achari, R; Laddu, AR; Somberg, JC, 1991) |
| "Clonidine is a centrally acting alpha 2-agonist whose clinical use has often been limited by the dose dependent side effects of dry mouth and sedation, and the belief that it should be given three times per day." | 2.37 | Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents. ( Anavekar, SN; Conway, EL; Drummer, OH; Howes, LG; Jarrott, B; Louis, WJ; McNeil, JJ; Workman, B, 1987) |
| "Terazosin is a new long-acting, selective alpha 1-adrenergic antagonist." | 2.37 | Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension. ( Eisen, G; Frishman, WH; Lapsker, J, 1988) |
| "Pretreatment with terazosin (10 mg/kg ip) significantly reduced the initial increase in MAP to 12 +/- 6 mmHg, whereas MAP for the last 45 min was superimposable on control values." | 1.32 | Sympathetic and angiotensin-dependent hypertension during cage-switch stress in mice. ( Brands, MW; Lee, DL; Webb, RC, 2004) |
| "Selected adverse events were evaluated from the combined randomized placebo-controlled clinical trials (once-a-day or twice-a-day; monotherapy or combination therapy) of terazosin in hypertensive patients." | 1.28 | Effect of age and dose on the incidence of adverse events in the treatment of hypertension in patients receiving terazosin. ( Hosmane, BS; Jordan, DC; Laddu, A; Maurath, CJ, 1992) |
| " In both the SHR and WKY, chronic administration of terazosin did not influence vascular concentrations of 3-methylhistidine, a biochemical marker for contractile proteins and vascular medial hypertrophy." | 1.28 | Effect of alpha 1-adrenoceptor blockade on the development of hypertension in the spontaneously hypertensive rat. ( Frewin, DB; Head, RJ; Jonsson, JR, 1992) |
| "Terazosin is a quinazoline antihypertensive agent that is chemically similar to prazosin." | 1.27 | Pharmacology of terazosin. ( Kyncl, JJ, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (33.33) | 18.7374 |
| 1990's | 51 (45.95) | 18.2507 |
| 2000's | 18 (16.22) | 29.6817 |
| 2010's | 3 (2.70) | 24.3611 |
| 2020's | 2 (1.80) | 2.80 |
| Authors | Studies |
|---|---|
| Ohyama, K | 1 |
| Hori, Y | 1 |
| Sugiura, M | 1 |
| Jiang, C | 1 |
| Jiang, X | 1 |
| Wang, X | 2 |
| Shen, J | 1 |
| Zhang, M | 1 |
| Jiang, L | 1 |
| Ma, R | 1 |
| Gan, T | 1 |
| Gong, Y | 1 |
| Ye, J | 1 |
| Gao, W | 1 |
| Farshi, A | 1 |
| DalirAkbari, N | 1 |
| Zomorrodi, A | 1 |
| Khalili, M | 1 |
| Mahmoudinezhad, M | 1 |
| Hua, CX | 1 |
| Hua, L | 1 |
| Li, N | 1 |
| Wang, L | 1 |
| Pang, HM | 1 |
| Ming, GH | 1 |
| Huang, Y | 1 |
| Cheng, XR | 1 |
| Liu, H | 2 |
| Wu, Y | 1 |
| Xu, L | 1 |
| Kang, J | 1 |
| Xu, ZM | 1 |
| Li, YS | 1 |
| Liu, P | 1 |
| Mao, G | 1 |
| Chen, G | 1 |
| Wang, B | 1 |
| Qin, X | 1 |
| Na, Y | 1 |
| Liu, Z | 1 |
| Xu, X | 1 |
| Yang, C | 1 |
| Li, YL | 1 |
| Fang, J | 1 |
| Zhang, X | 1 |
| Liu, HP | 1 |
| Qin, XH | 1 |
| Xu, XP | 1 |
| Chatziralli, IP | 1 |
| Sergentanis, TN | 1 |
| Wu, CS | 1 |
| Sung, SF | 1 |
| Tong, SH | 1 |
| Ong, CT | 1 |
| Bur, A | 1 |
| Woisetschläger, C | 1 |
| Herkner, H | 1 |
| Derhaschnig, U | 1 |
| Quehenberger, P | 1 |
| Hirschl, MM | 1 |
| Claxton, CR | 1 |
| Brands, MW | 2 |
| Fernández Salazar, L | 1 |
| Palencia García, A | 1 |
| Gong, P | 1 |
| Tang, J | 1 |
| Cheng, L | 1 |
| Lu, Z | 1 |
| Zhang, J | 1 |
| Zeng, F | 1 |
| Sugaya, K | 1 |
| Kadekawa, K | 1 |
| Ikehara, A | 1 |
| Nakayama, T | 1 |
| Gakiya, M | 1 |
| Nashiro, F | 1 |
| Goya, M | 1 |
| Hatano, T | 1 |
| Ogawa, Y | 1 |
| Zhang, WR | 1 |
| Sun, M | 1 |
| Luo, JK | 1 |
| Lee, DL | 1 |
| Webb, RC | 1 |
| Yang, MG | 1 |
| Zhao, XK | 1 |
| Osborn, JW | 1 |
| Collister, JP | 1 |
| Guzman, P | 1 |
| Kwak, C | 1 |
| Lee, JK | 1 |
| Ku, JH | 1 |
| Filyushina, EE | 1 |
| Shmerling, MD | 1 |
| Lazarev, VA | 1 |
| Buzuyeva, II | 1 |
| Markel', AL | 1 |
| Yakobson, GS | 1 |
| Frisk-Holmberg, M | 1 |
| Drayer, JI | 1 |
| Weber, MA | 2 |
| DeYoung, JL | 1 |
| Brewer, DD | 1 |
| Lowe, FC | 2 |
| Guthrie, R | 1 |
| Jerant, AF | 1 |
| Moon, L | 1 |
| Pfettscher, S | 1 |
| Elliott, WJ | 1 |
| Lenz, ML | 1 |
| Pool, JL | 4 |
| Laddu, AR | 5 |
| Varghese, A | 1 |
| Johnston, W | 1 |
| Taylor, AA | 2 |
| Rosenthal, J | 3 |
| Kyncl, JJ | 2 |
| Horky, K | 1 |
| Ram, CV | 1 |
| Ponikowski, P | 1 |
| Hańczycowa, H | 1 |
| Sebzda, T | 1 |
| Jurga, M | 1 |
| Spring, A | 1 |
| Rotter, A | 1 |
| Jordanek, P | 1 |
| Shionoiri, H | 1 |
| Gotoh, E | 1 |
| Ito, T | 1 |
| Hata, T | 1 |
| Iwatsubo, H | 1 |
| Takegawa, K | 1 |
| Ogihara, T | 1 |
| Mikami, H | 1 |
| Ikegami, H | 1 |
| Otsuka, A | 1 |
| Wang, W | 1 |
| Semplicini, A | 2 |
| Valle, R | 2 |
| Serena, L | 2 |
| Fazari, G | 1 |
| Fontebasso, A | 2 |
| Gebbin, A | 2 |
| De Toni, R | 2 |
| Pessina, AC | 2 |
| Gerardi, G | 1 |
| Cohen, J | 1 |
| Cardillo, C | 1 |
| Degen, C | 1 |
| Campia, U | 1 |
| De Felice, F | 1 |
| Folli, G | 1 |
| Scheen, AJ | 1 |
| McCarty, R | 1 |
| Lee, JH | 1 |
| Hernández Hernández, R | 1 |
| Angeli-Greaves, M | 1 |
| Carvajal, AR | 1 |
| Guerrero Pajuelo, J | 1 |
| Armas Padilla, MC | 1 |
| Armas-Hernández, MJ | 1 |
| Gomi, T | 2 |
| Ikeda, T | 2 |
| Ikegami, F | 1 |
| Schäfers, RF | 1 |
| Michel, MC | 1 |
| Suzuki, H | 1 |
| Achari, R | 6 |
| Hosmane, B | 2 |
| Linnen, P | 1 |
| Cavanaugh, J | 1 |
| Baroldi, P | 1 |
| Cohen, A | 2 |
| Setoguchi, M | 1 |
| Onaka, U | 1 |
| Abe, I | 1 |
| Hasuo, Y | 1 |
| Nishino, Y | 1 |
| Fujishima, M | 1 |
| Kirby, RS | 1 |
| Olson, PJ | 1 |
| Padley, RJ | 1 |
| Harris, SI | 1 |
| Alvarez, C | 1 |
| Pasanisi, F | 1 |
| Imperatore, G | 1 |
| Vaccaro, O | 1 |
| Iovine, C | 1 |
| Ferrara, LA | 1 |
| Antic, V | 1 |
| Kiener-Belforti, F | 1 |
| Tempini, A | 1 |
| Van Vliet, BN | 1 |
| Montani, JP | 1 |
| Bonacci, E | 1 |
| O'Dea, R | 1 |
| Shibuya, Y | 1 |
| Nagao, R | 1 |
| Suzuki, Y | 1 |
| Katoh, T | 1 |
| Isurugi, K | 1 |
| Obara, W | 1 |
| Omori, S | 1 |
| Goto, Y | 1 |
| Fujioka, T | 1 |
| Numasato, S | 1 |
| Chrischilles, E | 1 |
| Rubenstein, L | 1 |
| Chao, J | 1 |
| Kreder, KJ | 1 |
| Gilden, D | 1 |
| Shah, H | 1 |
| Ligueros, M | 1 |
| Unwin, R | 1 |
| Wilkins, MR | 1 |
| Humphreys, J | 1 |
| Coles, SJ | 2 |
| Cleland, J | 1 |
| Black, HR | 1 |
| Chrysant, SG | 3 |
| Curry, CL | 1 |
| Frishman, WH | 2 |
| Grimm, RH | 3 |
| Lasseter, KC | 1 |
| Okun, R | 1 |
| Raizada, V | 1 |
| Vlachakis, ND | 1 |
| Jonsson, JR | 1 |
| Head, RJ | 1 |
| Frewin, DB | 1 |
| Silke, B | 1 |
| Guy, S | 1 |
| Humphreys, JE | 1 |
| Laddu, A | 3 |
| Romero, E | 1 |
| Angeli, M | 1 |
| Velasco, M | 1 |
| Azar, E | 1 |
| Bueno, O | 1 |
| Lema, G | 1 |
| Morales, N | 1 |
| Nuchi, Y | 1 |
| Rasines, C | 1 |
| Wagner, A | 1 |
| Hosmane, BS | 1 |
| Maurath, CJ | 4 |
| Jordan, DC | 6 |
| Lytle, T | 1 |
| Coles, S | 1 |
| Waite, MA | 2 |
| Khoury, AF | 1 |
| Kaplan, NM | 1 |
| Strom, JA | 1 |
| Zola, B | 1 |
| Frishman, W | 1 |
| Wexler, JP | 1 |
| Carlson, K | 1 |
| Jordan, A | 1 |
| Somberg, JC | 1 |
| Cheung, DG | 1 |
| Luther, RR | 10 |
| Cohen, JD | 1 |
| Saunders, E | 1 |
| Lytle, TB | 1 |
| Klepper, MJ | 2 |
| Glassman, HN | 8 |
| Yasumoto, K | 2 |
| Takata, M | 2 |
| Yoshida, K | 2 |
| Mikawa, M | 2 |
| Tomoda, F | 2 |
| Sasayama, S | 2 |
| Liu, G | 1 |
| Louis, WJ | 1 |
| McNeil, JJ | 1 |
| Anavekar, SN | 1 |
| Conway, EL | 1 |
| Workman, B | 1 |
| Howes, LG | 1 |
| Drummer, OH | 1 |
| Jarrott, B | 1 |
| Estep, CB | 2 |
| Bal, IS | 1 |
| Johnson, B | 1 |
| McPherson, MA | 1 |
| Beretta-Piccoli, C | 3 |
| Ferrier, C | 3 |
| Weidmann, P | 3 |
| Sonders, RC | 1 |
| Sperzel, WD | 4 |
| Dauer, AD | 1 |
| Ruoff, G | 2 |
| Rudd, P | 1 |
| Deger, G | 1 |
| Mersey, JH | 1 |
| Mordasini, R | 1 |
| Steinberg, FJ | 1 |
| Horton, JK | 2 |
| Hayduk, K | 2 |
| Schneider, HT | 1 |
| Titmarsh, S | 1 |
| Monk, JP | 1 |
| Eisen, G | 1 |
| Lapsker, J | 1 |
| Schmitz, PJ | 1 |
| Nelson, EB | 1 |
| Mitchell, JR | 1 |
| Holtzman, JL | 1 |
| Kaihlanen, PM | 1 |
| Rider, JA | 1 |
| Lewin, AJ | 1 |
| Spindler, JS | 1 |
| Oberlin, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00693199] | 360 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia[NCT03144596] | Phase 4 | 63 participants (Actual) | Interventional | 2015-10-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 reviews available for terazosin and Blood Pressure, High
| Article | Year |
|---|---|
Risk factors for intraoperative floppy iris syndrome: a meta-analysis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Diabetes Complications; Doxazosin; Humans; Hypertension; In | 2011 |
[Progress in the studies of alpha1-adrenoceptor blocker for concurrent benign prostatic hyperplasia and hypertension].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Huma | 2007 |
Alpha 1-blockade in the management of hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Drug Therapy, Combination; Hu | 1993 |
Adrenergic mechanisms in left ventricular hypertrophy: significance and clinical implications.
Topics: Adrenergic alpha-Antagonists; Animals; Arrhythmias, Cardiac; Blood Pressure; Hemodynamics; Humans; H | 1993 |
Long-term efficacy and safety of terazosin.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hy | 1993 |
[Terazosin].
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Prazosin; Prostatic Hyperplasia | 1998 |
Treatment of benign prostatic hyperplasia and hypertension in elderly hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Aged; Female; Humans; Hypertension; Male; Multicenter Studies as Topic | 1998 |
Terazosin: a new alpha adrenoceptor blocking drug.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Drug Therapy, Combination; Hemodynamics; Humans; | 1992 |
Alpha-blocker therapy of hypertension. An unfulfilled promise.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Hypertension; Lipids; Prazosin | 1991 |
Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events.
Topics: Adrenergic alpha-Antagonists; Age Factors; Antihypertensive Agents; Dose-Response Relationship, Drug | 1991 |
Antihypertensive therapy: taking lipids into consideration.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 1991 |
Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 1991 |
The safety and efficacy of terazosin in the treatment of essential hypertension in blacks.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Black People; Double-Blind Metho | 1991 |
Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Blood Pressure; Clonidine; Doxazosin; Human | 1987 |
Terazosin: a new antihypertensive agent with favorable effects on lipids.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Humans; Hypertension; Lipids; Prazos | 1989 |
Blood pressure and lipid lowering effects of terazosin.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Coronary Disease; Humans; Hyp | 1989 |
alpha 1-antagonists in the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Doxazosin; Humans; Hypertensi | 1989 |
Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Double-Blind Method; Humans; Hypertension; P | 1986 |
Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Animals; Clinical Trials as Topic; Diuretics; Drug Therap | 1987 |
Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension.
Topics: Adrenergic alpha-Antagonists; Animals; Heart Failure; Humans; Hypertension; Prazosin | 1988 |
58 trials available for terazosin and Blood Pressure, High
| Article | Year |
|---|---|
A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Antihypertensive Agents; Carvedilol; Cross-Over Studi | 2021 |
[Efficacy of monotherapy with 15 antihypertensive agents in treating essential hypertension assessed by 24-hour ambulatory blood pressure monitoring].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2007 |
Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double-blind clinical trial.
Topics: Adrenergic alpha-Antagonists; Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy | 2009 |
[Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention].
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug T | 2009 |
[Effects of terazosine and atenolol on serum lipids in essential hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Ate | 2002 |
Effect of terazosin on blood pressure and serum lipids.
Topics: Antihypertensive Agents; Blood Pressure; Essential Hypertension; Humans; Hypercholesterolemia; Hyper | 1999 |
Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Hypertension; Male; Prazosin; Prostatic | 2003 |
[Serum nitric oxide and D-dimer before and after administering antihypertensive drugs in essential hypertension].
Topics: Adrenergic alpha-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 2003 |
High-dose terazosin therapy (5mg) in Korean patients with lower urinary tract symptoms with or without concomitant hypertension: a prospective, open-label study.
Topics: Adrenergic alpha-Antagonists; Aged; Asian People; Blood Pressure; Humans; Hypertension; Korea; Male; | 2007 |
Long-term BP monitoring in the evaluation of antihypertensive therapy.
Topics: Adult; Aged; Blood Pressure; Circadian Rhythm; Drug Evaluation; Humans; Hypertension; Male; Middle A | 1983 |
Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind M | 1994 |
Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Middle Aged; Prazosin; Primary Health Care | 1994 |
Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions.
Topics: Adult; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Heart Rate; Humans; H | 1995 |
Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Female; Glucose; Humans; Hypertension; Lipid Metabolism; | 1994 |
[Pressure and metabolic effects of terazosin in essential hypertension].
Topics: Adrenergic alpha-Antagonists; Adult; Atrial Natriuretic Factor; Blood Glucose; Double-Blind Method; | 1994 |
Comparison of the effects of terazosin and enalapril on laboratory stress testing blood pressure in patients with essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Double-Blind Method; Enalapril; Exercise Test; | 1993 |
Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive | 1996 |
Beneficial effect of alpha-blocker on hemorheology in patients with essential hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Viscosity; Erythrocyte Deformability; F | 1997 |
Effects of oral and intravenous terazosin and head-up tilt on blood pressure responses in patients with hypertension.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; | 1998 |
Comparative efficacies of a calcium antagonist and an alpha1 blocker in elderly hypertensive patients with stroke.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Aging; Blood Pressure Monitoring, Ambulatory; | 1998 |
Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressur | 1998 |
Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Hypertension; Male; Prazosin; Prostatic | 1999 |
Alpha 2-agonist versus alpha 1-antagonist in mild-to-moderate hypertension: comparison of transdermal clonidine and terazosin monotherapies.
Topics: Administration, Cutaneous; Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Adrenergic | 1997 |
Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in type 2 diabetic patients with hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Analysis of Variance; Area Under Curve; Blood Glucose; Choleste | 1999 |
The relationship between terazosin dose and blood pressure response in hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure M | 2000 |
[The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Prazos | 2001 |
A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension.
Topics: Adult; Atenolol; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hy | 1992 |
Antihypertensive and metabolic effects of concomitant administration of terazosin and methyclothiazide for the treatment of essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Double-Blind Method; Drug Administration | 1992 |
Comparison of antihypertensive and lipid actions of terazosin and atenolol in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Dose-R | 1992 |
Double-blind placebo-controlled trial of terazosin effect on blood pressure and urinary output of dopamine in hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Dopamine; Double-Blind Method; Female; Hu | 1992 |
A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with untreated essential hypertension.
Topics: Adolescent; Adrenergic alpha-Antagonists; Blood Pressure; Cholesterol; Female; Hospitals; Humans; Hy | 1991 |
Antihypertensive dose-response relationships: studies with the selective alpha 1-blocking agent terazosin.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitors; Dose | 1991 |
Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Female; Follow-Up Studies; Humans; Hypertensi | 1991 |
Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 1991 |
The safety and efficacy of terazosin in the treatment of essential hypertension in blacks.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Black People; Double-Blind Metho | 1991 |
A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with essential hypertension.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Cholesterol; Female; Human | 1991 |
The effects of terazosin and methyclothiazide on blood pressure and serum lipids.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Apolipoproteins; Blood Pressure; Cholesterol; Clinical Tr | 1989 |
alpha 1-antagonists in the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Doxazosin; Humans; Hypertensi | 1989 |
Antihypertensive effectiveness of terazosin: a new long-acting alpha-adrenergic inhibitor.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Humans; | 1985 |
Clinical trials with terazosin. General methods.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Clinical Trials as Topic; Dose-Response Relat | 1986 |
Terazosin: an effective once-daily monotherapy for the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Do | 1986 |
Effect of withdrawal of terazosin therapy in patients with hypertension.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Clinical Trials as Topic; Dizziness; Female; Follow-Up | 1986 |
Comparative trials of terazosin with other antihypertensive agents.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combina | 1986 |
Cumulative experience with terazosin administered in combination with diuretics.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Clinical Trials as Topic; Diuretics; Double-Blind Meth | 1986 |
Experience with terazosin administered in combination with other antihypertensive agents.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; | 1986 |
Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Do | 1986 |
Efficacy of terazosin as an antihypertensive agent.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Age Factors; Aged; Antihypertensive Agents; Black o | 1986 |
Efficacy and safety of intravenous terazosin in hypertensive patients. A preliminary report.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; | 1986 |
Alpha-1-adrenergic blockade and lipoprotein metabolism in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combina | 1986 |
Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Double-Blind Method; Humans; Hypertension; P | 1986 |
Efficacy and safety of doxazosin in hypertension therapy.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Clinical Trials as Topic; Double-Blind M | 1987 |
Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Double | 1987 |
Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Animals; Clinical Trials as Topic; Diuretics; Drug Therap | 1987 |
Terazosin for hypertension.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Humans; Hypertension; Prazosin | 1987 |
Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Female; Humans; Hypertension | 1988 |
Terazosin in mild hypertension: experience in open trials.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Clinical Trials as Topic; Female; Humans; Hypertension; M | 1987 |
Terazosin (Hytrin): cumulative experience of clinical trials in the USA for the treatment of mild to moderate essential hypertension.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Clinical Trials as Topic; Female; Humans; Hyp | 1987 |
Concomitant administration of terazosin and atenolol for the treatment of essential hypertension.
Topics: Adult; Aged; Atenolol; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; | 1988 |
38 other studies available for terazosin and Blood Pressure, High
| Article | Year |
|---|---|
Evaluation of syncope association with α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Doxazosin; Humans; Hypertension; Indoles; Male; Midd | 2019 |
Transdermal iontophoresis delivery system for terazosin hydrochloride: an
Topics: Administration, Cutaneous; Adrenergic alpha-1 Receptor Antagonists; Animals; Antihypertensive Agents | 2021 |
Multiple cerebral infarctions related to famotidine-induced eosinophilia.
Topics: Acarbose; Adrenergic alpha-1 Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulc | 2012 |
Nitric oxide opposes glucose-induced hypertension by suppressing sympathetic activity.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Enzyme Inhibitor | 2003 |
[Hepatotoxicity induced by terazosin].
Topics: Adrenergic alpha-Antagonists; Chemical and Drug Induced Liver Injury; Humans; Hypertension; Liver; L | 2003 |
Sympathetic and angiotensin-dependent hypertension during cage-switch stress in mice.
Topics: Angiotensins; Animals; Atenolol; Blood Pressure; Heart Rate; Housing, Animal; Hypertension; Male; Mi | 2004 |
Effect of peripheral sympathetic nerve dysfunction on salt sensitivity of arterial pressure.
Topics: Animals; Antihypertensive Agents; Autonomic Nervous System Diseases; Blood Pressure; Dose-Response R | 2008 |
Delayed effects of hypotensive drugs on structural characteristics of the renal glomerular system in hypertensive NISAG rats.
Topics: Animals; Antihypertensive Agents; Enalapril; Hypertension; Kidney Glomerulus; Losartan; Male; Nifedi | 2007 |
Effect of clonidine at steady state on blood pressure in spontaneously hypertensive rats. Interaction of various alpha-adrenoceptor antagonists.
Topics: Adrenergic alpha-Antagonists; Animals; Benzimidazoles; Blood Pressure; Clonidine; Dioxanes; Drug Int | 1984 |
Terazosin for BPH.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Humans; Hypertension; Male; Prazosin; Prosta | 1995 |
Hytrin treatment of hypertension and benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Prazosin; Prostatic Hyperplasia | 1995 |
An individualized approach to the hypertensive patient with renal disease: six illustrative case studies.
Topics: Adrenergic alpha-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Arterial Occlusive Dis | 1995 |
Clinical applications of alpha 1-receptor blockade: terazosin in the management of hypertension. Introduction.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Prazosin; Receptors, Adrenergic, alpha-1 | 1993 |
[Effect of enalapril and terazosin on lipid metabolism in patients with essential arterial hypertension and accompanying hypercholesterolemia].
Topics: Adrenergic alpha-Antagonists; Adult; Enalapril; Female; Humans; Hypercholesterolemia; Hypertension; | 1993 |
[The effect of terazosin and nitrendipine on blood insulin, glucose and lipid in SHR rats].
Topics: Adrenergic alpha-Antagonists; Animals; Blood Glucose; Female; Hypertension; Insulin; Lipids; Prazosi | 1993 |
Long-term alpha-1 adrenoceptor blockade does not affect plasma atrial natriuretic peptide in hypertensive patients.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Atrial Natriuretic Fac | 1994 |
[Pharma-clinics. Drug of the month. Terazosine (Hytrin)].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Hypertension; Male; Middle Aged; Praz | 1995 |
Preweanling administration of terazosin decreases blood pressure of hypertensive rats in adulthood.
Topics: Adrenergic alpha-Antagonists; Aging; Animals; Animals, Suckling; Blood Pressure; Drug Administration | 1996 |
Role of the sympathetic nervous system during the development of obesity-induced hypertension in rabbits.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Blood Pressure D | 2000 |
Effects of antihypertensive treatment on platelet function in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; bet | 2000 |
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
Topics: Accidental Falls; Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Cohort Studies; Comor | 2001 |
Effect of alpha 1-adrenoceptor blockade on the development of hypertension in the spontaneously hypertensive rat.
Topics: Adrenergic alpha-Antagonists; Animals; Biomarkers; Blood Pressure; Body Weight; Hemodynamics; Hypert | 1992 |
Effect of age and dose on the incidence of adverse events in the treatment of hypertension in patients receiving terazosin.
Topics: Adolescent; Adult; Age Factors; Aged; Dose-Response Relationship, Drug; Humans; Hypertension; Middle | 1992 |
Clinical model for antihypertensive therapy in the 1990s: the role of alpha1 blockade. Proceedings of a symposium. Irving, Texas, November 8-10, 1990.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Prazosin | 1991 |
Acute hemodynamic effects of terazosin in hypertensive and normotensive patients.
Topics: Adrenergic alpha-Antagonists; Cardiac Catheterization; Dose-Response Relationship, Drug; Drug Evalua | 1991 |
Efficacy of terazosin in the treatment of essential hypertension in blacks.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Black People; Female; Humans; Hypertension; M | 1990 |
Effects of terazosin on serum lipid levels in hypertensive blacks.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Black People; Female; Humans; Hypertension; L | 1990 |
Reversal of left ventricular hypertrophy by terazosin in hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Aged; Cardiomegaly; Drug Evaluation; Electrocardiography; Female; Hear | 1990 |
[Effects of terazocin on hypertensive patients].
Topics: Adrenergic alpha-Antagonists; Adult; Female; Humans; Hypertension; Male; Middle Aged; Prazosin | 1990 |
Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Female; Hemodynamics; Humans; Hypertension; Male; Middle | 1989 |
Alpha 1-adrenergic blockade and cardiovascular pressor responses in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Cardiovascular System; Drug Interactions; Elect | 1986 |
Advances in the management of hypertension: focus on terazosin, a new alpha1-adrenergic antagonist. May 3-5, 1985, Boca Raton, Florida.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Piperazines; Prazosin | 1986 |
Pharmacology of terazosin.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Chemical Phenomena; Che | 1986 |
Pharmacokinetics of terazosin.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Animals; Blood Proteins; Chemical Phenomen | 1986 |
Long-term experience with terazosin for treatment of mild to moderate hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Dru | 1986 |
Overall safety of terazosin as an antihypertensive agent.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Asthenia; Body Weight; Dizziness; Female; Hea | 1986 |
First European review of terazosin. Proceedings of a symposium. Reykjavik, Iceland, 29th-31st May 1987.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Prazosin | 1987 |
Cardiovascular effects of short-term selective alpha 1-adrenergic blockade with terazosin in patients with essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; | 1985 |